NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Aclaris Therapeutics, Inc. ACRS
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.8M
▼ 58.2% vs FY2024
EPS · FY25
$-0.53
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-50.2%
Net margin · FY25
-829.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.8M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 830 cents on every revenue dollar this year.
Per share
USD -0.53
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-50.2%
Return on equity, FY2025
ROE
Operating margin-975.9%
Net margin-829.6%
Return on assets-34.1%
Each USD of equity lost 50 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+3.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−35.9%
+3.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+72.0%
Change, 10 years—
The share count grew 72% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 160.5M
total assets, end of FY2025
Total assetsUSD 160.5M
EquityUSD 103.1M
CashUSD 20.0M
Current ratio3.36×
Equity funds 64% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
−0.0
·
·
−0.0
·
·
−0.0
·
·
·
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.53
−1.71
−1.27
−1.33
−1.60
−1.20
−3.90
−4.03
−2.44
−2.25
−3.79
−6.15
−6.45
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−50.2
−84.5
−49.9
−44.0
−77.3
−94.9
−113.2
−60.3
−34.7
−36.7
−57.3
·
·
Shares out B
0.12
0.11
0.07
0.07
0.06
0.05
0.04
0.04
0.03
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed